Skip to main
OMCL
OMCL logo

Omnicell (OMCL) Stock Forecast & Price Target

Omnicell (OMCL) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 39%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Omnicell Inc. is experiencing a positive trajectory in its financial performance, highlighted by the increasing contribution of Advanced Services to total revenue, which is projected to represent 52% of 2024 estimated revenue, demonstrating a focus on innovative solutions such as the compounding robot-as-a-service. The company's revised guidance for the fourth quarter implies significant growth expectations, with revenue and adjusted EBITDA anticipated to rise by 11% and 34%, respectively, underscoring an improving sales environment for healthcare technology investments. Additionally, the strategic review has positioned Omnicell to enhance synergies and recurring revenues, which now account for approximately 50% of total revenues, thereby supporting a sustainable growth outlook in the medication management sector.

Bears say

Omnicell Inc. is experiencing a challenging financial landscape, characterized by a decline in AEBITDA margin, which has decreased by 150 basis points year-over-year to 10.5%. The company's revenue growth estimate for 2025 has been moderated to 6%, down from a prior estimate of 9%, indicating a cautious outlook due to the anticipated slowing in the XT replacement cycle, despite growth in services revenue. Additionally, delays in the launch of the new IVX compounding robot due to regulatory redesign issues pose potential risks to future product sales and overall revenue performance.

Omnicell (OMCL) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 39% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omnicell and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omnicell (OMCL) Forecast

Analysts have given Omnicell (OMCL) a Buy based on their latest research and market trends.

According to 18 analysts, Omnicell (OMCL) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omnicell (OMCL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.